Participation in the Eastern Cooperative Oncology Group

描述(由申请人提供)：新泽西州癌症研究所(CINJ)是NCI指定的综合癌症中心，致力于开展与癌症教育、预防、诊断和治疗相关的实验室、临床和转化性研究。自最近成立以来，联合国儿童基金会和我们对经社理事会的参与稳步增长，我们承诺在以下方面向经社理事会提供更多的资源：应计(3年应计284项和434项后续行动)、委员会参与(17项委员会参与)、礼宾领导(7项积极研究和1项提交的研究)和出版物(23项)。CINJ最近还获得批准，成为ECOG预防中心，并成为ECOG症状管理联盟的成员。CINJ的几名调查人员已经获得了NCI资助的经社理事会相关研究补助金的批准。基于我们患者基础的持续增长(每年4000例新病例)，我们附属网络的增长(18家医院有14,000例新病例)，以及我们对ECOG在多个疾病领域积累的承诺，我们预计我们的应计、我们的科学和我们的管理角色将继续增长。因此，CINJ将成为该集团较大的主要成员贡献者之一。我们建议使用这笔赠款：1)继续我们在ECOG疾病导向、管理和模式委员会的代表；2)设计并积极参与新的多模式研究；3)提供同行评审、资助的机构实验室作为小组科学的潜在资源；4)监测患者进入、方案遵从性和数据质量；5)及时提交完整的数据表；6)与ECOG其他成员合作，继续在CINJ开展试点研究；以及7)加强我们的基础科学实验室与小组临床试验计划之间的互动。

DESCRIPTION (provided by applicant): The Cancer Institute of New Jersey (CINJ) is an NCI Designated Comprehensive Cancer Center committed to the conduct of laboratory, clinical, and translational research relevant to cancer education, prevention, diagnosis and treatment. CINJ and our participation in ECOG have grown steadily since CINJ's recent inception, and we are committing even greater resources to ECOG in accrual (3year accrual of 284 and 434 follow-up), committee participation (17 committee participations), protocol leadership (7 active and 1 submitted study), and publications (23). CINJ also recently received approval as an ECOG Prevention Center, and as a member of the ECOG Symptom Management Consortium. Several of the CINJ investigators already received approval for NCI-funded ECOG correlative studies grants. Based on the continued growth of our patient base (>4000 new cases/year), the growth of our Affiliate Network (18 hospitals with >14,000 new cases), and our commitment to ECOG accrual in multiple disease areas, we expect our accrual, our scientific and our administrative roles to continue to grow. CINJ is thus positioned to become one of the larger main member contributors to the group. We propose to use this grant to: 1) continue our representation on ECOG disease oriented, administrative, and modality committees; 2) design and participate actively in new multi-modality studies; 3) offer peer reviewed, funded institutional laboratories as potential resources for group science; 4) monitor patient entry, protocol compliance, and data quality; 5) submit complete data forms in a timely manner, 6) continue development of pilot studies at the CINJ in collaboration with other ECOG members ; and 7) enhance interaction between the our basic science laboratories and the group's clinical trials program.